Clinical trials
Prostatitis clinical trials
Below are recruiting prostatitis clinical trials, each written for real people, not researchers. We’re tracking 1,360 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06542757Recruiting
Focused radiation to main prostate tumor using MRI guidance
This trial tests a stronger, more focused radiation dose to the main tumor inside the prostate using MRI guidance. It aims to improve control of intermediate-risk prostate cancer while possibly reducing side effects.
New York, New YorkAges 18 years+ - NCT06523634Recruiting
SBRT for rising PSA after prostate removal
This trial tests a precise type of radiation (called SBRT) to the prostate bed for men whose PSA starts rising after prostate removal surgery. It aims to see if this targeted approach can effectively treat the recurrence without needing long-term hormone therapy.
AalstAges 18 years+ - NCT06517719Recruiting
Real-world study of Pluvicto for advanced prostate cancer
This study looks at how men with advanced prostate cancer (mCRPC) do when they receive a treatment called Pluvicto (lutetium vipivotide tetraxetan) in real-world settings. It aims to collect information on treatment effectiveness and quality of life without adding any extra procedures or medications.
Konstanz, Baden-WurttembergAges 18–99 - NCT06531499RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
Los Angeles, CaliforniaAges 18–100 - NCT06511141Recruiting
Nerve stimulation for men with overactive bladder
This study tests a nerve stimulation device placed near the tailbone to help men with overactive bladder symptoms. If you have bothersome urinary urgency or frequency, this treatment may offer relief without drugs.
Birmingham, AlabamaAges 18 years+ - NCT06499870RecruitingPhase 2
Study of two drugs with radiation for high-risk prostate cancer
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
Chicago, IllinoisAges 18 years+ - NCT05786742Recruiting
Radiation plan test for early prostate cancer with a boost
This trial tests a more concentrated radiation schedule for early-stage prostate cancer, using an extra high-dose “boost” delivered from inside the body. It may help by treating the prostate more precisely while aiming to keep side effects manageable.
QuébecAges 18–95 - NCT06482645Recruiting
Testing a new biopsy method for prostate cancer diagnosis
This study is testing a new approach to prostate biopsy that takes samples from around a suspicious area seen on MRI. It aims to see if this method can better detect prostate cancer compared to standard biopsy.
Beijing, Beijing MunicipalityAges 45–85 - NCT06487507Recruiting
Mediterranean diets for men before prostate surgery
This study tests whether a medically designed Mediterranean diet can help men before prostate cancer surgery. You would eat special foods and be monitored closely to see how the diet affects your health and recovery.
Miami, FloridaAges 18–80 - NCT06474806RecruitingPhase 2
PET scan for untreated prostate cancer
This trial tests a new type of PET scan that looks for a protein called uPAR on prostate cancer cells. It might help doctors see your cancer more clearly without needing surgery or treatment first.
Herlev, CopenhagenAges 18 years+ - NCT06470685Enrolling by invitation
Preventive prostate removal for prostate cancer risk
This study tests whether removing the prostate before cancer develops can help people at higher risk, such as those with certain gene changes (like BRCA2), a strong family history, or Black African/Caribbean ancestry. It also includes people who have already had their prostate removed for cancer treatment.
LondonAges 18 years+ - NCT06472817Enrolling by invitation
Social factors affecting prostate cancer care in African and Caribbean men
This study looks at how social and cultural factors affect prostate cancer care and long-term health in Black immigrant men from Sub-Saharan Africa and the Caribbean. Your experiences can help improve cancer care for others like you.
Atlanta, GeorgiaAges 18 years+ - NCT06446401Recruiting
Triple vs double therapy for widespread prostate cancer
This trial compares two treatment approaches for men whose prostate cancer has spread widely and is still responding to hormone therapy. It tests whether using three drugs together (triple therapy) works better than two drugs (double therapy) to control the cancer longer.
Uppsala, Region UppsalaAges 18 years+ - NCT06457919RecruitingPhase 1/Phase 2
Tinengotinib with standard treatments for advanced prostate cancer
This study tests a new drug called tinengotinib combined with standard treatments for men with advanced prostate cancer that has stopped responding to abiraterone or enzalutamide. The goal is to see if the combination can help control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT06451445Recruiting
Focal IRE treatment for intermediate-risk prostate cancer
This trial tests a new focal treatment called IRE (irreversible electroporation) that uses electrical pulses to destroy prostate cancer cells while sparing healthy tissue. It is for men with intermediate-risk prostate cancer that has not spread outside the prostate gland.
Toronto, OntarioAges 50 years+ - NCT06424275Enrolling by invitation
Prostate cancer screening trial for European men ages 50-69
This trial aims to raise awareness and screen for prostate cancer in men aged 50 to 69 across the European Union. You may be able to join if you have never been diagnosed with prostate cancer and haven't had a prostate biopsy or MRI in the last six months.
DublinAges 50–69 - NCT06437574RecruitingPhase 2
Cholesterol-lowering and immune response in prostate cancer
This trial tests whether taking a daily cholesterol-lowering medication (Vytorin or ezetimibe) can boost your immune system to help fight prostate cancer. It is for men with low- or intermediate-risk prostate cancer who are on active surveillance and planning a biopsy.
Los Angeles, CaliforniaAges 18 years+ - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Los Angeles, CaliforniaAges 18 years+ - NCT06409910RecruitingPhase 2
Comparing shorter radiation treatments for prostate cancer
This study tests two slightly different short-course radiation schedules for men who have had their prostate removed and are now getting follow-up radiation. The goal is to see if one is more effective or has fewer side effects.
London, OntarioAges 18 years+ - NCT06406803Recruiting
Exercise vs. diet for prostate cancer patients before surgery
This study compares the effects of exercise and a low-calorie diet on how your body builds proteins in your tumor and muscles. It may help men with prostate cancer who are about to have surgery.
HasseltAges 18 years+ - NCT06408298RecruitingEarly Phase 1
Hydroxychloroquine before prostate cancer surgery
This trial tests whether a drug called hydroxychloroquine (HCQ) can help before prostate cancer surgery. It is for people with localized prostate cancer who are planning to have their prostate removed.
Lebanon, New HampshireAges 18 years+ - NCT06401980RecruitingPhase 2
Darolutamide for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
AarauAges 18 years+ - NCT06402357RecruitingPhase 2
Focused Ultrasound for Recurrent Prostate Cancer After Radiation
This trial tests if a focused ultrasound treatment can safely and effectively treat prostate cancer that has come back after radiation therapy. The ultrasound uses sound waves to heat and destroy cancer cells in a specific area of the prostate while sparing healthy tissue.
Gainesville, FloridaAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+
Hear when a new Prostatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostatitis?
- Yes. Clin2 currently lists 1,360 recruiting prostatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.